LY6D and cancer: Under normal physiological conditions, LY6D is most commonly used as a marker of early B cell lineage; however, in response to genotoxic stressors such as radiation and chemotherapy, LY6D expression is upregulated in numerous cancer types and is suggested to contribute to distant metastasis in breast cancer [41–43].